Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Supply readiness follows months of manufacturing to ensure timely and ample supply
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
Subscribe To Our Newsletter & Stay Updated